✦ LIBER ✦

PD-147 A phase I study of a second generation antisenseoligonucleotide to clusterin (OGX-011) in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Preliminary results

✍ Scribed by Laskin, J.; Chi, K.; Melosky, B.; Sill, K.; Hao, D.; Canil, C.; Gleave, M.; Murray, N.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Irinotecan plus gemcitabine vs irinoteca

✍ Georgoulias, V; Kouroussis, C; Agelidou, A; Boukovinas, I; Palamidas, P; Stavrin 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

O-91 First line treatment with gemcitabi

✍ Esteban, Emilio; Fra, Joaquin; Vietez, Jose María; Palacio, Isabel; De Sande, Jo 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 331 KB

PD-068 An exploratory analysis of a phas

✍ Bunn, P.; Rosell, R.; Fossella, F.; Perry, M.; Stahel, R.; Barata, F.; Nguyen, B 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 142 KB

A phase I/randomized phase II, non-compa

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB